drugset / Trial / NCT00344942

Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults

NCT00344942

Phase 3 Terminated 77 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort versus placebo in adult patients presenting with Chronic Non Allergic and Non Infectious Rhinitis

Timeline

Start
2006-04
Primary completion
2007-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 220 ug Intranasal

Indications